Hybrid aptamer conjugated Au-dendrimer nanostructure as a targeted delivery system against colon adenocarcinoma
Paper ID : 1179-ICNS
Marzieh Mohammadi *1, Mohammad Ramezani2, Mona Alibolandi3
1Department of pharmaceutics, school of pharmacy, Mashhad University of medical sciences
2Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences
3Department of Pharmaceutical Biotechnology, Mashhad University od Medical Sciences
Mucine 1 (MUC-1) receptor is a heterodimeric protein which is frequently overexpressed in most solid tumors. Specific targeting of the cancer cells using nanocarriers would enhance the therapeutic efficiency and reduce the associated adverse effects. In the current study, we used a DNA aptamer against MUC-1 receptor covalently conjugated to our newly developed theranostic nanocarrier made of PAMAM dendrimer covalently conjugated to gold nanoparticles to combine targeted therapy based on specific diagnostic tests. The targeted hybrid nanostructure was about 5 nm in size and positively charged. The release assay showed that the cytotoxic agent was released in a sustained manner up to 5 days. Additionally, the nanocarrier could efficiently accumulate in MUC-1 positive cell lines and induced significantly higher cytotoxicity. Besides, the in vivo experiment demonstrated the designed theranostic system was effectively used in CT-scan tumor imaging. The findings of the study demonstrated that our novel hybrid aptamer conjugated Au-dendrimer nanostructure provided good X-ray attenuation while showed high therapeutic efficiency against colorectal cancer adenocarcinoma.
“Gold nanoparticle” “PAMAM” “Muc-1” “Theranostic” “Aptamer”
Status : Abstract Accepted (Poster Presentation)